{"nctId":"NCT01749904","briefTitle":"Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension","startDateStruct":{"date":"2013-01-31","type":"ACTUAL"},"conditions":["Open-Angle Glaucoma","Ocular Hypertension"],"count":420,"armGroups":[{"label":"BOL-303259-X","type":"EXPERIMENTAL","interventionNames":["Drug: BOL-303259-X"]},{"label":"Timolol","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Timolol","Drug: BOL-303259-X"]}],"interventions":[{"name":"BOL-303259-X","otherNames":[]},{"name":"Timolol","otherNames":[]},{"name":"BOL-303259-X","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participants must have a diagnosis of OAG (including pigmentary or pseudoexfoliative) or OHT in 1 or both eyes.\n* Participants must meet the following IOP requirements at Visit 3\n* mean/median IOP ≥ 24 mmHg at a minimum of 2 time points in the same eye\n* IOP ≤ 36 mmHg at all 3 measurement time points in both eyes.\n* Participants with a best-corrected visual acuity (BCVA), using the Early Treatment of Diabetic Retinopathy Study (ETDRS) protocol, of +0.7 logMAR units (Snellen equivalent of approximately 20/100) or better in either eye.\n\nExclusion Criteria:\n\n* Participants with known hypersensitivity or contraindications to latanoprost, NO treatment, timolol maleate, other beta-adrenergic receptor antagonists or any of the ingredients in the study drugs.\n* Participants with a central corneal thickness greater than 600 μm in either eye.\n* Participants with advanced glaucoma and participants with a cup/disc ratio greater than 0.8 or a history of split fixation, or a field loss threatening fixation in either eye.\n* Participants who do not have an intact posterior capsule in either eye .\n* Participants with aphakia in either eye.\n* Participants with previous or active corneal disease in either eye.\n* Participants with current or a history of severe dry eye in either eye.\n* Participants with current or a history of optic disc hemorrhage in either eye.\n* Participants with current or a history of central/branch retinal vein or artery occlusion in either eye.\n* Participants with current or a history of macular edema in either eye.\n* Participants with very narrow angles (3 quadrants with less than Grade 2 according to Shaffer's anterior chamber angle grading system) and Participants with angle closure,congenital, and secondary glaucoma, and participants with history of angle closure in either eye.\n* Participants with a diagnosis of a clinically significant or progressive retinal disease in either eye.\n* Participants with any intraocular infection or inflammation in either eye within 3 months(90 days) prior to Visit 1 (Screening).\n* Participants with a history of ocular laser surgery in either eye within the 3 months(90 days) prior to Visit 1 (Screening).\n* Participants with a history of incisional ocular surgery or severe trauma in either eye within 3 months (90 days) prior to Visit 1 (Screening).","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean IOP","description":"Mean intraocular pressure (IOP) in study eye measured at the specified time points: 8 AM, 12 PM, and 4 PM at Visit 4(Week 2), Visit 5 (Week 6), and Visit 6 (Month 3).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.61","spread":"3.544"},{"groupId":"OG001","value":"19.84","spread":"3.651"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.00","spread":"3.376"},{"groupId":"OG001","value":"19.37","spread":"3.696"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.09","spread":"3.293"},{"groupId":"OG001","value":"19.20","spread":"3.359"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.59","spread":"3.525"},{"groupId":"OG001","value":"19.63","spread":"3.243"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.84","spread":"3.305"},{"groupId":"OG001","value":"19.09","spread":"3.230"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.82","spread":"3.513"},{"groupId":"OG001","value":"19.09","spread":"3.492"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.71","spread":"3.382"},{"groupId":"OG001","value":"19.73","spread":"2.230"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.88","spread":"3.409"},{"groupId":"OG001","value":"19.15","spread":"3.311"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.83","spread":"3.521"},{"groupId":"OG001","value":"19.15","spread":"3.643"}]}]}]},{"type":"SECONDARY","title":"Response Rate - IOP ≤ 18 mm Hg","description":"Percentage of participants with IOP ≤ 18 mm Hg consistently at all 9 time points in the first 3 months","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"Response Rate - IOP Reduction ≥ 25%","description":"Percentage of participants with IOP reduction ≥ 25% consistently at all 9 time points in the first 3 months","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99","spread":null},{"groupId":"OG001","value":"26","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Ocular and Systemic Adverse Events","description":"Following assessments through Visit 6 (Month 3), all participants, irrespective of previous randomization, converted to a single open label safety arm receiving BOL-303259-X QD in the evening. Adverse events were recorded throughout the comparative efficacy phase and open label extension phase.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"19","spread":null},{"groupId":"OG002","value":"62","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"16","spread":null},{"groupId":"OG002","value":"46","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":283},"commonTop":["Eye irritation"]}}}